血小板减少首发的IgG4相关性疾病1例报道
IgG4-Associated Disease That Starts with Thrombocytopenia: A Case Report
DOI: 10.12677/ACM.2023.132295, PDF,   
作者: 刘建德, 冉建民*：暨南大学附属广州红十字会医院，广东 广州
关键词: IgG4相关性疾病；免疫性血小板减少症；个案报道；IgG4-Associated Disease； Immune Thrombocytopenia； Case Report
摘要: IgG4相关性疾病(IgG4-RD)是一种较为罕见的免疫介导的慢性炎症性疾病，目前确切的病因及发病机制尚不清楚，我国尚无流行病学数据，临床表现多样，可累及全身多个器官组织，糖皮质激素为该病的一线治疗药物。该文报道1例以血小板减少为首发症状的IgG4-RD男性患者，因四肢指(趾)端散发性瘀斑1月入院，经糖皮质激素治疗后，复查血小板逐步上升，未再有出现瘀点瘀斑，随访情况稳定。
Abstract: IgG4-associated disease (IgG4-RD) is a rare immune-mediated chronic inflammatory disease. The exact etiology and pathogenesis of IGG4-RD are still unclear, and there are no epidemiological data in China. The clinical manifestations are diverse and can involve multiple organs and tissues in the whole body. Glucocorticoid is the first-line treatment for this disease. In this paper, a male IgG4-RD patient with thrombocytopenia as the first symptom was admitted to hospital for sporadic ecchy-mosis on the fingers (toes) of the limbs for 1 month. After glucocorticoid therapy, the platelet grad-ually increased and no petechial ecchymosis appeared again. The follow-up was stable.
文章引用：刘建德, 冉建民. 血小板减少首发的IgG4相关性疾病1例报道[J]. 临床医学进展, 2023, 13(2): 2113-2116. https://doi.org/10.12677/ACM.2023.132295

参考文献

[1] Stone, J.H., Khosroshahi, A., Deshpande, V., et al. (2012) Recommendations for the Nomenclature of IgG4-Related Disease and Its Individual Organ System Manifestations. Arthritis & Rheumatism, 64, 3061-3067. [Google Scholar] [CrossRef] [PubMed]
[2] Kamisawa, T., Zen, Y., Pillai, S. and Stone, J.H. (2015) IgG4-Related Dis-ease. Lancet, 385, 1460-1471. [Google Scholar] [CrossRef] 
[3] 张文, 董凌莉, 朱剑, 刘燕鹰, 赵岩, 曾小峰, 张抒. IgG4相关性疾病诊治中国专家共识[J]. 中华内科杂志, 2021, 60(3): 192-206.
[4] 申媛文, 林鹭, 郁胜强. IgG4相关性疾病的管理和治疗: 2015年国际共识解读[J]. 中国实用内科杂志, 2015, 35(12): 1011-1013.
[5] 季兰岚, 张卓莉. IgG4相关疾病诊断及治疗的国际专家共识[J]. 中华风湿病学杂志, 2016, 20(8): 576.
[6] Takahashi, H., Yamamoto, M., Suzuki, C., et al. (2010) The Birthday of a New Syndrome: IgG4-Related Diseases Constitute a Clinical Entity. Autoimmunity Reviews, 9, 591-594. [Google Scholar] [CrossRef] [PubMed]
[7] Stone, J.H., Zen, Y. and Deshpande, V. (2012) IgG4-Related Disease. The New England Journal of Medicine, 366, 539-551. [Google Scholar] [CrossRef] 
[8] Ebbo, M., Daniel, L., Pavic, M., et al. (2012) IgG4-Related Systemic Disease: Features and Treatment Response in a French Cohort: Results of a Multicenter Registry. Medicine, 91, 49-56. [Google Scholar] [CrossRef] 
[9] Raina, A., Yadav, D., Krasinskas, A.M., et al. (2009) Evalu-ation and Management of Autoimmune Pancreatitis: Experience at a Large US Center. American Journal of Gastroenter-ology, 104, 2295-2306. [Google Scholar] [CrossRef] [PubMed]
[10] Lanzillotta, M., Fernàndez-Codina, A., Culver, E., et al. (2021) Emerging Therapy Options for IgG4-Related Disease. Expert Review of Clinical Immunology, 17, 471-483. [Google Scholar] [CrossRef] 
[11] Yoshifuji, H. and Umehara, H. (2022) Glucocorticoids in the Treatment of IgG4-Related Disease-Prospects for New International Treatment Guidelines. Modern Rheumatology, Article ID: roac097. [Google Scholar] [CrossRef] [PubMed]
[12] Khosroshahi, A., Wallace, Z.S., Crowe, J.L., et al. (2015) International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthri-tis & Rheumatology, 67, 1688-1699. [Google Scholar] [CrossRef] [PubMed]
[13] Zhang, W. and Stone, J. (2019) Management of IgG4 Related Disease. Lan-cet Rheumatology, 1, 55-65. [Google Scholar] [CrossRef] 
[14] Wu, Q., Chang, J., Chen, H., et al. (2017) Efficacy between High and Medium Doses of Glucocorticoid Therapy in Remission Induction of IgG4-Related Diseases: A Preliminary Randomized Controlled Trial. International Journal of Rheumatic Diseases, 20, 639-646. [Google Scholar] [CrossRef] 
[15] Li, J., Peng, Y., Zhang, Y., et al. (2020) Identifying Clinical Sub-groups in IgG4-Related Disease Patients Using Cluster Analysis and IgG4-RD Composite score. Arthritis Research & Therapy, 22, Article No. 7. [Google Scholar] [CrossRef] [PubMed]
[16] Fei, Y., Peng, Y., et al. (2019) Efficacy and Safety of Low Dose Mycophenolate Mofetil Treatment for Immunoglobulin G4-Related Disease: A Randomized Clinical Trial. Rheumatology, 58, 52-60. [Google Scholar] [CrossRef] [PubMed]
[17] Wang, L., Zhang, P., Wang, M., et al. (2018) Failure of Remis-sion Induction by Glucocorticoids Alone or in Combination with Immunosuppressive Agents in IgG4-Related Disease: A Prospective Study of 215 Patients. Arthritis Research & Therapy, 20, Article No. 65. [Google Scholar] [CrossRef] [PubMed]
[18] Liu, Y., Zeng, Q., Zhu, L., et al. (2020) Relapse Predictors and Serologically Unstable Condition of IgG4-Related Disease: A Large Chinese Cohort. Rheumatology, 59, 2115-2123. [Google Scholar] [CrossRef] [PubMed]
[19] Fukui, S., Nakai, T., Kawaai, S., et al. (2022) Advantages of an Alternate-Day Glucocorticoid Treatment Strategy for the Treatment of IgG4-Related Disease: A Preliminary Retrospec-tive Cohort Study. Medicine, 101, e30932. [Google Scholar] [CrossRef] 

为你推荐